Research & Development
Universal CAR-T Platform

Gene-Editing Free:
A Safer Foundation

REVO-U is designed to create a next-generation universal CAR-T product without plasmids, nucleases, or DNA double-strand breaks.

No plasmids. No nucleases. No DNA damage. Protein-directed TCR surface elimination supports a safer allogeneic CAR-T foundation.
CAR molecule TCR-CD3 complex CD3 degradation IMPDH Armor
A source T cell is shown beside an engineered CAR-T cell. Purple CAR molecules and green Armor span the engineered cell membrane, with IMPDH inside. Arrows lead from the endoplasmic reticulum to TCR-CD3 complex disassembly and CD3 element degradation. The nucleus and DNA are retained. A six-item molecular legend identifies the components. IMPDH Revo-U Engineering TCR-CD3complexdisassembly CD3elementsdegradation No plasmids. No nucleases. No DNA damage. Protein-directed TCR elimination for a saferallogeneic CAR-T foundation. CAR molecule TCR-CD3 complex CD3 elements CD3 elements IMPDH Armor Source T cell above, engineered CAR-T cell below, followed by the molecular legend. CAR and Armor span the engineered membrane. Internal arrows show TCR-CD3 disassembly and CD3 degradation. IMPDH Revo-U Engineering TCR-CD3complexdisassembly CD3elementsdegradation CAR molecule CD3 elements TCR-CD3 complex CD3 elements IMPDH Armor
Why It Matters

Why a Next-Generation Universal CAR-T Platform Is Needed

Conventional universal CAR-T strategies often require multiple gene edits plus CAR transduction. REVO‑U is designed to simplify manufacturing while reducing phenotype heterogeneity.

Typical genes edited:

  • TCR
  • HLA-A
  • HLA-B / B2M
  • CD52
  • CIITA

+ CAR transduction by LVV

Conventional universal CAR-T

REVO‑U

Safety Concerns

Off-target risk and chromosome translocation concerns from gene editing.

More Natural Biology

Non-gene-editing approach to handle GvHD or HvGR; no DNA double-strand breaks and no chromosome translocation risk.

Complex Supply Chain and High COGS

Expensive electroporation devices and GMP-grade materials such as gRNAs, dsDNA, Cas9 proteins and LVV.

Simple CMC & Low COGS

Manufacturing process similar to autologous CAR-T, requiring only LVV; no plasmids needed throughout the process.

High Heterogeneity

Variable gene-editing efficiency can lead to heterogeneous phenotypes and residual GvHD risk from CAR+TCR+ cells.

High Purity

Near-100% CAR+TCR− phenotype in the final product.

Poor Scalability

Lengthy multi-step processes can contribute to poor cell function and limited yields.

Great Scalability

Up to 3,000 doses per batch using one clean-room unit in short time; manufacturing capacity expandable with limited investment.
Four phenotypes are shown: CAR-positive TCR-negative at upper left, CAR-positive TCR-positive at upper right with GvHD risk, CAR-negative TCR-negative at lower left, and CAR-negative TCR-positive at lower right. The CAR-positive TCR-negative phenotype is highlighted. CAR expression is the vertical axis; TCR expression is the horizontal axis. CAR+ TCR− CAR+ TCR+ CAR− TCR− CAR− TCR+ GvHD risk TCR expression CAR expression
CAR and TCR expression

Phenotypic combinations

The combination of multiple gene edits and CAR transduction can create many possible phenotypic combinations.

The next-generation platform is scalable to industrial-scale manufacturing, comparable to biologic drugs.

Manufacturing Advantage

Industrial-Scale Manufacturing

REVO‑U is designed for large batch output with a streamlined workflow, moving from complex gene-edited production toward biologics-like scalability.

Gene-edited Universal CAR-T

25–100doses per batch

High cost

  1. Collect donor cells
  2. Activate T cells
  3. CAR transduction
  4. Gene editing
  5. Expand & QC
  6. Fill doses

Multi-step edited-cell manufacturing workflow

REVO‑U Manufacturing

Up to 3,000doses per batch

Scalable like biologics

A bioreactor connects by an arrow to three filled vials.
Final Product Profile

High phenotypic purity

Protein-directed TCR surface elimination creates a phenotypically uniform, safer cell population.

Residual GvHD risk

Near-100%

CAR+ TCR−

Phenotype schematic

Functional Enhancement

Enhanced Cell Fitness & Persistence

REVO‑U combines IMPDH-mediated MPA resistance with a proprietary co-stimulatory armor module to support long-term functional persistence.

IMPDH

MPA resistance

Functional outcomes

  • Survival
  • Anti-exhaustion
  • Long-term persistence

Armor

A proprietary co-stimulatory armor module supports survival, resistance to exhaustion, and long-term persistence.

  • North Area, Building E, Floors 3-4, Qianhai Shenzhen-Hong Kong Youth Innovation Hub, Nanshan District, Shenzhen, Guangdong Province, China
  • 0755-86971801

微信公众号

Copyright © 2024 Wondercel Therapeutics Powered by vancheer